View all News & Blog posts »
View all projects »
View all publications »
Interactive data visualizations of antibiotic use and resistance in North America and Europe
The Board of Directors of the Center for Disease Dynamics, Economics & Policy is comprised of men and women representing the business community, public helath organizations, former policymakers, as well as pre-eminent scholars. The board provides overall direction for the organization and meets twice annually. Members are eligible to serve for three three-year terms.
CDDEP is deeply committed to bringing to the board, in ever-greater numbers, leading figures from outside the United States as well as representatives of minority populations from North America.
Professional affiliations of board members are listed for identification purposes only.
Sir George Alleyne
Professor, Management and Law
Professor, Department of Economics
University of Maryland
Edward F. Hand
George W. Bickerstaff III
Center for Disease Dynamics, Economics & Policy
Sir George, OCC, M.D., F.R.C.P., F.A.C.P. (Hon), DSc (Hon), a native of Barbados, was appointed by the UN Secretary-General in February 2003 to serve as his Special Envoy for HIV/AIDS in the Caribbean Region.
Dr. Alleyne joined the Pan-American
Health Organization (PAHO) in 1981 as chief of Research Promotion and
Coordination. From 1995 to 2003 he served as Director of PAHO.
Dr. Alleyne entered academic medicine in UWI in 1962, and his career included research in the Tropical Metablism Research Unit for his Doctorate in Medicine. In 1990, Dr. Alleyne was made Knight Bachelor by Queen Elizabeth II for his services to medicine and, in 2001; he was awarded the Order of the Caribbean Community. In July 2003, the Caribbean Community (Caricom) appointed Dr. Alleyne as the head of a new commission to examine health issues confronting the region, including HIV/AIDS, and their impact on national economies. In October 2003, he was appointed Chancellor of the University of the West Indies.
Mark Cohen is an expert on government
enforcement of policy mandates, having published more than 85 articles and
books on such topics as the effect of community right-to-know laws on firm
behavior; why companies reduce toxic chemical emissions; benefit-cost analysis
of oil spill regulation and enforcement; whether it "pays" to be
green; and judicial sentencing of individuals and firms convicted of corporate
He has served on various governmental advisory panels, including Tennessee’s Environmental Justice Steering Committee and the U.S. Environmental Protection Agency’s Science Advisory Board Panel on Illegal Competitive Advantage and Economic Benefits. He is a member of the Stakeholder Council of the Global Reporting Initiative, and serves on several academic editorial boards including Journal of Benefit-Cost Analysis, Environmental Economics, and Managerial and Decision Economics.
Cohen is a professor of management at the Owen Graduate School of Management at Vanderbilt University and holds a secondary appointment at Vanderbilt as a professor of law. Previously, he was a staff economist at the U.S. Environmental Protection Agency, the U.S. Federal Trade Commission, and the U.S. Sentencing Commission.
At Vanderbilt, he has taught such courses as Economics of Organizations, Corporate Strategies for Environmental and Social Responsibility, and the Law and Business of Climate Change. He co-founded and directed the Vanderbilt Center for Environmental Management Studies, and from 2003-2005 he was senior associate dean of the Owen Graduate School.
Maureen Cropper, a professor of
economics at the University of Maryland and a former lead economist at the
World Bank, returned to RFF in 2008 as a senior fellow, a position she held
from 1990 to 1993. Cropper has made major contributions to environmental policy
through her research, teaching, and public service. Her research has focused on
valuing environmental amenities, estimating consumer preferences for health and
longevity improvements, and the tradeoffs implicit in environmental
regulations. Previously, at the World Bank, her work focused on improving
policy choices in developing countries through studies of deforestation, road
safety, urban slums, and health valuation. She is currently studying the
externalities associated with pandemic flu control, the impact of reforms in
the electric power sector in India and the demand for fuel economy in the
Indian car market.
From 1995 to 1996, Cropper was president of the Association of Environmental and Resource Economists. From 1994 through 2006, she served on the U.S. Environmental Protection Agency's Science Advisory Board, where she chaired the Advisory Council for Clean Air Act Compliance Analysis and the Environmental Economics Advisory Committee. She is a research associate of the National Bureau of Economic Research and a member of the National Academy of Sciences.
Edward Hand is the vice president for finance and administration at Resources for the Future. He has been at RFF since 1980 and is responsible for all its financial and administrative functions including investment management, real estate operations, budgeting, accounting, contracting, human resources, communications, and information systems. Before coming to RFF Mr. Hand was the assistant comptroller at the Naval Intelligence Support Center. He served 26 years in the Navy and Naval Reserve retiring as a Captain in 1995. Mr. Hand holds a BA degree from Brown University and an MBA from George Washington University.
Ramanan Laxminarayan directs the Center for Disease Dynamics, Economics & Policy. He is also a visiting scholar and lecturer at Princeton University. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He has worked to improve understanding of drug resistance as a problem of managing a shared global resource.
Laxminarayan has worked with the World Health Organization (WHO) and the World Bank on evaluating malaria treatment policy, vaccination strategies, the economic burden of tuberculosis, and control of non-communicable diseases. He has served on a number of advisory committees at WHO, Centers for Disease Control and, Prevention, and the Institute of Medicine. In 2003-04, he served on the National Academy of Science/Institute of Medicine Committee on the Economics of Antimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. His work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC, NPR, Reuters, Science, Wall Street Journal, and National Journal.
Adel A. F. Mahmoud, M.D., Ph.D, is at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University . He has recently retired as President of Merck Vaccines and member of Management Committee of Merck & Company, Inc. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998.
Dr. Mahmoud's academic pursuits focused on investigations of the biology and function of eosinophils particularly in host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006, including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. Dr. Mahmoud's leadership in setting strategies for Global Health shaped the agenda of the Forum on Microbial Threats of the Institute of Medicine in recent years by tackling topical issues such as biological threats and bioterrorism; SARS; Pandemic Flu and others. He is an active contributor to scientific literature and authored and edited several textbooks and reports.
Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London , School of Hygiene and Tropical Medicine in 1971. He was elected to membership of the American Society for Clinical Investigation in 1978, the Association of American Physicians in 1980 and the Institute of Medicine of the National Academy of Sciences in 1987. He received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983, and the Squibb Award of the Infectious Diseases Society of America in 1984. Dr. Mahmoud is a fellow of the American College of Physicians and a member of the Expert Advisory Panel on Parasitic Diseases of the World Health Organization. He served on the National Advisory Allergy and Infectious Diseases Council and is a past president of the Central Society for Clinical Research and the International Society for Infectious Diseases. He is currently serving as a member of the National Science Advisory Board for Biosecurity and Committee on Scientific Communications and National Security (CSCANS) of the National Academy of Sciences.
Sir Richard is currently Professor of Medical Statistics and Epidemiology at the University of Oxford, and co-director (with Professor Sir Rory Collins) of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU). He was made a Fellow of the Royal Society of London in 1989 for introducing meta-analyses of randomised trials, was knighted by Queen Elizabeth in 1999 for services to epidemiology and received in 2010 the inaugural Cancer Research UK Lifetime Achievement Award.
Richard Peto, Rory Collins and the Oxford CTSU have, by their large randomised trials, large prospective studies and worldwide meta-analyses, increased substantially the estimated importance of blood lipids, blood pressure and smoking as causes of premature death, and their publications have attracted more than 60,000 citations. Peto’s investigations into the worldwide health effects of smoking have helped to communicate effectively the vast and growing burden of disease from tobacco use, have helped change national and international attitudes about smoking and public health, and have helped many smokers to stop. He was the first to describe clearly the future worldwide health effects of current smoking patterns, predicting one billion deaths from tobacco in the present century, as against “only” 100 million in the 20th century. He has recently collaborated in major studies of alcohol in Russia and of malaria in Africa and south Asia, and was a member of the committee responsible for the 2004 IOM report on the economics of anti-malarial drugs.
Mr. George W. Bickerstaff, III is the Managing Director of M.M. Dillon & Co., LLC. Prior to that, he was a Managing Director at CRT Capital Group specializing in healthcare banking from 2005. Prior to joining CRT Capital Group George was Chief Financial Officer of Novartis Pharma AG located in Basel, Switzerland. George has been instrumental in establishing the strategic, operating and financial direction of numerous private and public companies. During his career he has provided financial leadership for mergers and acquisitions valued at more than $50 billion and has funded and operated various venture capital businesses.
George has a broad range of operating and finance experiences. After receiving engineering and business degrees, he started his career at General Electric in manufacturing and then moved into finance. He subsequently joined The Dun & Bradstreet Corporation where he held various senior finance positions including Chief Financial Officer of IMS Health, the largest global publicly traded healthcare information services provider. George has been on the board of directors and board of trustees of more than a dozen international private and public companies and philanthropic organizations. He has been a guest speaker on global finance at various international industry associations and graduate business schools, including Harvard Business School.